<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431456</url>
  </required_header>
  <id_info>
    <org_study_id>DARINA</org_study_id>
    <nct_id>NCT01431456</nct_id>
  </id_info>
  <brief_title>Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery</brief_title>
  <acronym>DARINA</acronym>
  <official_title>A Randomized Pilot Study Comparing the Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martini Hospital Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martini Hospital Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      After total knee arthroplasty (TKA) surgery, patients are at risk to develop venous&#xD;
      thromboembolism (VTE) or deep venous thrombosis (DVT) potentially resulting in a fatal&#xD;
      pulmonary embolism (PE). Two novel agents, dabigatran and rivaroxaban, recently gained market&#xD;
      authorisation for prevention of venous thromboembolism after knee arthroplasty.&#xD;
&#xD;
      However, there are no clinical trials with dabigatran and/or rivaroxaban and the comparator&#xD;
      nadroparin.&#xD;
&#xD;
      Nadroparin is used in the most Dutch departments of orthopaedic surgery after total knee&#xD;
      arthroplasty. Also safety of the new oral agents with long term use of 42 days is not&#xD;
      available for total knee arthroplasty.&#xD;
&#xD;
      Our aim is to compare the long term use of dabigatran and rivaroxaban versus nadroparin on&#xD;
      safety after total knee arthroplasty (TKA) in a clinical explorative pilot study by observing&#xD;
      the incidence of major bleeding and clinical relevant non-major bleeding using a standardized&#xD;
      model of bleeding definitions.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The primary objective of this study is to compare the clinical safety with long term use of&#xD;
      the oral once daily unmonitored thrombin inhibitors dabigatran and rivaroxaban versus&#xD;
      subcutaneous administered nadroparin by observing the incidence of major bleeding and&#xD;
      clinical relevant non-major bleeding in patients after knee arthroplasty surgery.&#xD;
&#xD;
      The secondary objectives of this study are effectivity of the agents, compliance, hospital&#xD;
      stay, re-hospitalisation, outpatient clinic visits and interventions following complications.&#xD;
      Additionally, coagulation monitoring, knee flexion range of motion, Knee injury and&#xD;
      Osteoarthritis Outcome Score (KOOS), Knee Society Score (KSS) and relationship between health&#xD;
      statuses and surgery parameters will be evaluated.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      The study is designed as non-inferiority randomized open label controlled pilot study. A&#xD;
      total of 150 patients will be included, 50 patients in each treatment group (dabigatran,&#xD;
      rivaroxaban and nadroparin).&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients â‰¥ 18 years and weighing more than 40 kg, participate in the 'joint care program' for&#xD;
      primary elective total knee arthroplasty and want to provide signed informed consent are&#xD;
      eligible for the study.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Patients receive subcutaneously nadroparin or oral rivaroxaban or oral dabigatran after knee&#xD;
      replacement surgery.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      The primary safety outcome is the incidence of bleeding events occurring during the study&#xD;
      period of 135 days (including follow-up). Major bleeding events and clinically relevant&#xD;
      non-major bleeding events were defined according to accepted guidelines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety outcome is the incidence of bleeding events occurring during the study period of 135 days (including follow-up). Major bleeding events and clinically relevant non-major bleeding events were defined according to accepted guidelines</measure>
    <time_frame>135 days</time_frame>
    <description>Major and clinically relevant non-major bleeding</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dabigatran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nadroparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nadroparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Dabigatran</description>
    <arm_group_label>Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin</intervention_name>
    <description>Nadroparin</description>
    <arm_group_label>Nadroparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients &gt; 18 years and weighing more than 40 kg who are scheduled for primary elective&#xD;
        total knee arthroplasty according to the 'joint care program' and want to provided signed&#xD;
        informed consent are eligible for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a known inherited or acquired clinically significant active high risk of bleeding or&#xD;
             bleeding disorder;&#xD;
&#xD;
          -  major surgery, trauma, uncontrolled severe arterial hypertension, or myocardial&#xD;
             infarction within the last 3 months;&#xD;
&#xD;
          -  history of acute intracranial disease or hemorrhagic stroke;&#xD;
&#xD;
          -  gastrointestinal or urogenital bleeding or ulcer disease within the last 6 months;&#xD;
&#xD;
          -  cirrhotic patients with moderate hepatic impairment (aspartate or alanine&#xD;
             aminotransferase (AST, ALT) levels higher than 2x the upper limit of the normal range&#xD;
             (ULN) within the last month);&#xD;
&#xD;
          -  severe renal insufficiency (creatinine clearance &lt; 30 mL/min);&#xD;
&#xD;
          -  treatment with anticoagulants during study drug treatment;&#xD;
&#xD;
          -  active malignant disease;&#xD;
&#xD;
          -  pregnancy or breastfeeding;&#xD;
&#xD;
          -  and unable to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2011</study_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martini Hospital Groningen</investigator_affiliation>
    <investigator_full_name>Marinus van Hulst</investigator_full_name>
    <investigator_title>Hospital Pharmacist</investigator_title>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>venous thromboembolism after knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nadroparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

